Contineum Therapeutics (CTNM) completed the enrollment of 168 patients in its phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis.
The trial is designed to assess safety and efficacy by evaluating multiple clinical and imaging endpoints sensitive to remyelination changes in RRMS patients, the company said. The last patient is expected to complete the trial by Q3.
PIPE-307 is being developed under a global license and development agreement between Continuum and Janssen Pharmaceutica, a unit of Johnson & Johnson (JNJ).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.